Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community

Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View all publications

Priority Report

Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer
Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer
Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer
Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome
Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups
Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer
Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer
SABCS 2019: Updates in HER2+ Breast Cancer   >   Articles
Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer
Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer
Management of Diarrhea in Breast Cancer   >   Videos
Practical Perspectives on the Diagnosis and Treatment of Hairy Cell Leukemia
Practical Perspectives on the Diagnosis and Treatment of Hairy Cell Leukemia
Therapeutic Advances in Hairy Cell Leukemia   >   Articles
Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer
Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer
Management of Diarrhea in Breast Cancer   >   Videos
Next Page >>
Publication Bottom Border
Border Publication
 
x